Christopher Davis
Director, Nonclinical and Translational Research Apertura Gene Therapy
Dr. Christopher Davis is Director of Nonclinical and Translational Research at Apertura Gene Therapy. Prior to joining Apertura, Dr. Davis performed postdoctoral research with Dr. Michael Greenberg at Harvard Medical School, where his research focused on the impact of sensory experience on gene regulatory programs and the development of diverse cell types in the brain. Dr. Davis earned his B.S. in Molecular Biology summa cum laude with departmental honors from the University of Pittsburgh and Ph.D. in Genetics and Genomics from Harvard University.
Seminars
Thursday 26th February 2026
Roundtable: Discussing Strategies to Design Potency Assays Earlier in The Pipeline to De-risk IND & Clinical Trial Readiness
1:45 pm
- Discussing how to integrate potency assay design into early R&D so that assays are relevant, reproducible, and fit for regulatory expectations at IND stage
- Evaluating how early potency assay choices reduce risk of late-stage delays, bridging studies, or regulatory feedback loops
- Reviewing emerging tools, including ddPCR-based functional assays, FACS, in vitro surrogate models, that allow faster and more reliable potency readouts
